The Effects of Glucomannan on Weight Loss
This study has been completed.
Sponsor:
New York Chiropractic College
Information provided by (Responsible Party):
Denise Holtzman MS DC, New York Chiropractic College
ClinicalTrials.gov Identifier:
NCT01709955
First received: October 16, 2012
Last updated: October 17, 2012
Last verified: October 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine if the herb, Glucomannan, is an effective non-pharmacological appetite suppressant for overweight or Class I obese patients. The study design will not include any other lifestyle changes which enhance weight loss in order to completely isolate the effects of Glucomannan as a non-pharmacological appetite suppressant.
| Condition | Intervention | Phase |
|---|---|---|
|
Obesity |
Dietary Supplement: Glucomannan Other: Placebo |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Factorial Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
Resource links provided by NLM:
Further study details as provided by New York Chiropractic College:
Primary Outcome Measures:
- Weight Loss [ Time Frame: 30 Days ] [ Designated as safety issue: No ]
| Enrollment: | 43 |
| Study Start Date: | February 2011 |
| Study Completion Date: | July 2011 |
| Primary Completion Date: | July 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Gucomannan |
Dietary Supplement: Glucomannan
750 MG of Glucomannan in capsule form
|
| Placebo Comparator: Placebo pill |
Other: Placebo
750 mg of Cellulose powder in a capsule form
|
Eligibility| Ages Eligible for Study: | 21 Years to 60 Years (Adult) |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:Subjects will be recruited based upon the category of them wanting to lose 50 pounds.
Subjects must be able to swallow the capsule whole with water.
Exclusion Criteria:
- Self-reported use of prescription medication other than hormonal birth control (such as medication for diabetes, hypertension hypothyroidism, heart disease, cancer, etc.)
- Pregnancy
- Age younger than 21 or older than 60 years of age.
- Screening for hypertension during the first laboratory visit that reveals a systole greater than 120 and a diastole greater than 90.
- BMI calculations based upon height and weight measurements at the first laboratory visit that reveal a BMI less than 25 or greater than 35.
- Self-reported iron-deficiency anemia, osteoporosis, and hypoglycemia.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
No Contacts or Locations Provided
No Contacts or Locations Provided
More Information
| Responsible Party: | Denise Holtzman MS DC, Associate professor, New York Chiropractic College |
| ClinicalTrials.gov Identifier: | NCT01709955 History of Changes |
| Other Study ID Numbers: | 10-13 |
| Study First Received: | October 16, 2012 |
| Last Updated: | October 17, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by New York Chiropractic College:
|
Obesity Overweight Glucomannan |
Additional relevant MeSH terms:
|
(1-6)-alpha-glucomannan Cathartics Gastrointestinal Agents |
ClinicalTrials.gov processed this record on September 23, 2016